3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
83
Neoplasm Metastasis
9
Prostatic Neoplasms, Castration-Resistant
5
Neoplasms
3
Metastatic Castration-Resistant Prostate Cancer
3
Castration-resistant Prostate Cancer
3
Carcinoma, Non-Small-Cell Lung
3
Urogenital Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Primary Myelofibrosis
2
Pancreatic Neoplasms
2
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocytosis
1
Prostatic Diseases
1
Prostate Cancer Metastatic Disease
1
Prostate Adenocarcinoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
1
Ovarian Neoplasms
1
Interventions
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
×
abiraterone
×
Genitourinary
×
Clear all
NCT01780220
2022-05-19
CARLHA
UNICANCER
Phase 1/2
Completed
47 enrolled